Company aims to secure a partner to advance neflamapimod into Phase 3 for DLB
Company expects to present nfvPPA Phase 2a biomarker data in Q4 2026 and Q1 2027
CervoMed anticipates dosing first ALS patient in EXPERTS-ALS trial by end of 2026
Overview
US biotech developer's Q2 net loss was lower than analyst expectations
Company completed $20.5 mln equity financings, extending cash runway through Q3 2027
Company prioritizing strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Beat
$6.60 mln
$8.56 mln (6 Analysts)
Result Drivers
Grant revenue decline - Co said completion of Phase 2b RewinD-LB trial led to no grant revenue in Q2 2026, compared to $1.8 mln in Q2 2025
R&D expenses lower - Co attributed decrease in R&D expenses to completed RewinD-LB trial and other clinical/nonclinical costs, offset by increased manufacturing and personnel costs
CRVO•
